Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of …
| Métrica | OXB.L | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 39.1% | 57.4% | -18.3% |
| Operating Margin | -13.3% | -34.4% | +21.1% |
| Net Margin | -17.9% | -32.5% | +14.6% |
| FCF Margin | -2.5% | -12.6% | +10.1% |
| ROE | -33.0% | -39.2% | +6.2% |
| ROA | — | -30.9% | — |
| Current Ratio | 2.20 | 2.73 | -0.53 |
| Debt / Equity | 0.45 | 0.28 | +0.17 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | — | — |
| ✓Flujo de caja operativo positivo | £507,000 | −£51M |
| –Rentabilidad sobre activos al alza | — | — |
| –Caja operativa/activos supera al ROA | — | — |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 2.20 | 2.28 |
| ✗Sin aumentar el nº de acciones | — | — |
| ✗Margen bruto al alza | 39.1% | 41.2% |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -2.5% |
| ✓Ventas > 5 %/año (3 años) | 6.4% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 5.8% |
OXFORD BIOMEDICA PLC cotiza a 5.09 GBP y tiene una capitalización bursátil de £616M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud